The World Health Organization and the European Society of Intensive Care Medicine issued recommendations in November 2020 advising against the use of remdesivir for COVID-19

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Ebola, polio, epidemic preparedness, outbreak containment, and global health security.